BIOMAT Database Logo BIOMAT Database Logo

High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults. 1998

K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.

The prognosis in patients with primary brain tumors treated with surgery, radiotherapy and conventional chemotherapy remains poor. To improve outcome, combination high-dose chemotherapy (HDC) has been explored in children, but rarely in adults. This study was performed to determine the tolerability of three-drug combination high-dose thiotepa (T) and etoposide (E)-based regimens in pediatric and adult patients with high-risk or recurrent primary brain tumors. Thirty-one patients (13 children and 18 adults) with brain tumors were treated with high-dose chemotherapy: 19 with BCNU (B) and TE (BTE regimen), and 12 with carboplatin (C) and TE (CTE regimen). Patients received growth factors and hematopoietic support with marrow (n = 15), peripheral blood progenitor cells (PBPC) (n = 11) or both (n = 5). The 100 day toxic mortality rate was 3% (1/31). Grade III/IV toxicities included mucositis (58%), hepatitis (39%) and diarrhea (42%). Five patients had seizures and two had transient encephalopathy (23%). All patients had neutropenic fever and all pediatric patients required hyperalimentation. Median time to engraftment with absolute neutrophil count (ANC) >0.5 x 10(9)/l was 11 days (range 8-37 days). Time to ANC engraftment was significantly longer (P = 0.0001) in patients receiving marrow (median 14 days, range 10-37) than for PBPC (median 9.5 days, range 8-10). Platelet engraftment >50 x 10(9)/l was 24 days (range 14-53 days) in children. In adults, platelet engraftment >20 x 10(9)/l was 12 days (range 9-65 days). In 11 patients supported with PBPC, there was a significant inverse correlation between CD34+ dose and days to ANC (rho = -0.87, P = 0.009) and platelet engraftment (rho = -0.85, P = 0.005), with CD34+ dose predicting time to engraftment following HDC. Overall, 30% of evaluable patients (7/24) had a complete response (CR) (n = 3) or partial response (PR) (n = 4). Median time to tumor progression (TTP) was 7 months, with an overall median survival of 12 months. These TE-based BCNU or carboplatin three-drug combination HDC regimens are safe and tolerable with promising response rates in both children and older adults.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
September 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
September 1999, Journal of neuro-oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors.
May 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
November 1999, Medical and pediatric oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
December 2019, International journal of clinical oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma.
October 2019, Cancer chemotherapy and pharmacology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
May 2004, Cancer,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.
October 2007, Seminars in hematology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
December 2014, Journal of neuro-oncology,
K P Papadopoulos, and J H Garvin, and M Fetell, and L T Vahdat, and T J Garrett, and D G Savage, and C Balmaceda, and J Bruce, and M Sisti, and S Isaacson, and R De LaPaz, and R Hawks, and E Bagiella, and K H Antman, and C S Hesdorffer
Myeloablative Carboplatin and Thiotepa With Autologous Stem Cell Rescue for Nonmedulloblastoma High-risk CNS Tumors in Young Children.
November 2021, Journal of pediatric hematology/oncology,
Copied contents to your clipboard!